Delivery of transgene encoding vaccine antigen

"Delivery of transgene encoding vaccine antigen" is not a specific molecule or receptor but describes a methodological approach in vaccine design, particularly for cancer immunotherapy, where transgenes encoding tumor antigens (e.g., neoantigens like OVA, Alg8, Lama4, or GP100) are introduced into cells such as autologous T cells (Tvax) or viral vectors to elicit immune responses[1]. This process leverages cross-presentation by host dendritic cells (DCs) in lymphoid tissues to prime CD8+ and CD4+ T cell responses, often enhanced by co-expressed adjuvants like membrane-tethered IL-12 (mtIL-12), GM-CSF, CD137L, or IFN-β for stronger polyfunctional T cell activation and tumor rejection in preclinical models[1]. In DNA vaccine contexts, transgene delivery uses systems like gene guns, electroporation, or microparticles to boost antigen expression in DCs, promoting Th1-biased responses against antigens such as HPV E6/E7[2]. Viral vectors like modified vaccinia Ankara (MVA) deliver transgenes for neoantigens (TG4050), MUC1 (TG4010), or HPV E6/E7 (TG4001) to induce antigen-specific immunity in cancers[4][5][6]. It plays no direct role in disease pathology but enables therapeutic strategies targeting **cancer** (e.g., sarcoma, melanoma, cervical cancer) by breaking tolerance to self-antigens or neoantigens[1][2][6]. No drugs directly "target" this as it lacks a molecular structure; instead, it represents delivery platforms with challenges like variable DC uptake, T cell clearance, and toxicity from adjuvants (e.g., systemic IL-12 effects mitigated by tethering)[1]. This is not a standard therapeutic target like a receptor or enzyme, making it unsuitable for conventional drug interactions or patient selection biomarkers[1][2].